Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.43 |
| ▸ | ITGAV | P06756 | 8/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2899622 | 0.92 | ITGB3 (0.51) | ITGB3ITGAVITGA2BSMN1; SMN2L3MBTL1 | |
| SCHEMBL2907613 | 0.84 | ITGB3 (0.44) | ITGB3ITGAVITGA2BSMN1; SMN2L3MBTL1 | |
| SCHEMBL2906935 | 0.83 | FAAH (0.38) | ITGB3ITGAVITGA2BF2R | |
| SCHEMBL2927339 | 0.77 | ITGB3 (0.41) | ITGB3ITGAVITGA2BSMN1; SMN2L3MBTL1 | |
| SCHEMBL2902881 | 0.76 | ITGB3 (0.52) | ITGB3ITGAVITGA2BF2R | |
| SCHEMBL2902129 | 0.75 | ITGB3 (0.43) | ITGB3ITGAVITGA2BF2R | |
| SCHEMBL2906882 | 0.74 | ITGB3 (0.47) | ITGB3ITGAVITGA2B | |
| SCHEMBL2901789 | 0.74 | ITGB3 (0.37) | ITGB3ITGAVITGA2B | |
| SCHEMBL2925954 | 0.72 | ITGB3 (0.40) | ITGB3ITGAVITGA2BF2R | |
| SCHEMBL2901065 | 0.70 | YAP1 (0.33) | ITGB3ITGAVITGA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217569-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | Janssen Pharmaceutica N.V. (BE) | 2010-08-18 | — | — | EP | claimed |
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-14 | — | — | US | claimed |
| WO-2009058314-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | claimed |
| EP-2217569-B1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-16 | — | — | EP | disclosed |
| US-8680278-B2 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| EP-2217569-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | Janssen Pharmaceutica N.V. (BE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-14 | — | — | US | disclosed |
| WO-2009058314-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | ITGA5, ITGA1, ITGB5 | ITGB3 13/4885ITGAV 8/4885ITGA2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.